$LQDA

Krepp Sarah sold $17K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 276 shares of Liquidia Corp (LQDA) at $60.87 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Jun 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 designation and small dollar amount reduce expected market impact.

03

What to watch

The disclosure does not indicate intent beyond the pre-arranged plan, and the sale size ($16.8k) is small relative to typical institutional trading flows.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-03, disclosing a 2026-06-01 insider sale.

Background

The article is an SEC Form 4 insider transaction filing for Liquidia Corp, reported by an officer (Chief Human Resource Officer).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Krepp Sarah, Chief Human Resource Officer, sold 276 shares at $60.87 on 2026-06-01 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports an open-market sale with a pre-arranged 10b5-1 plan, providing no new company fundamentals or guidance in the text.

Market effects

No sector-level implications; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may interpret insider selling as a signal of reduced confidence, especially if multiple insiders sell around the same period.

Key entities

  • Liquidia Corp

    US-listed company subject of the Form 4 insider transaction disclosure.

  • Krepp Sarah

    Chief Human Resource Officer who sold 276 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient